- Merger certainty removed regulatory overhang
- Home health revenue grew 5.2% year-over-yearPublic.com
- Hospice segment showed 4.1% revenue-per-day increase
- Diversification into non-Medicare payers (20% growth)
How to Buy Amedisys, Inc. (AMED) Shares - Investment in Amedisys, Inc. (AMED) Stock
Updated on 01 Sep 2025
Thinking about investing in healthcare's home-based care revolution? Amedisys, Inc. (AMED) represents a unique opportunity at the intersection of aging populations and healthcare innovation. With the recent UnitedHealth merger completion, this stock offers both stability and growth potential. Let's explore why AMED deserves your attention and how to strategically position yourself in this evolving market.
Article navigation
- 📈 Amedisys Stock: Current Price and Critical Dates
- 📊 6-Month Price Journey (March-August 2025)
- 🔮 Price Forecast: 2025-2030
- ⚠️ Key Risks vs. Positive Signals
- 🛡️ What Should a Beginner Trader Do Today?
- ✅ How to Buy Amedisys, Inc. (AMED) Shares – Step by Step
- 💡 Why Pocket Option Fits Healthcare Investors
- 🌍 Amedisys in 2025: Home Healthcare Transformed
📈 Amedisys Stock: Current Price and Critical Dates
As of September 1, 2025, Amedisys, Inc. (AMED) trades at $100.99 on the NASDAQ exchange. This price reflects the recent completion of the landmark $3.3 billion acquisition by UnitedHealth Group, which officially closed on August 14, 2025Hospice News.
Mark your calendar: November 5, 2025 is absolutely critical. That’s when Amedisys releases its Q3 earnings report – the first full quarter under UnitedHealth ownership. Historically, these reports have moved prices significantly.
How Earnings Reports Move AMED Stock
| Date | Event | Pre-News Price | Post-News Change |
|---|---|---|---|
| Jul 29, 2025 | Q2 Earnings | $97.50 | +3.5% (beat estimates) |
| Apr 29, 2025 | Q1 Earnings | $94.20 | +2.8% (revenue growth) |
| Feb 25, 2025 | Annual Results | $92.80 | +4.1% (strong guidance) |
| Oct 29, 2024 | Q3 Earnings | $90.10 | +1.9% (steady performance) |
| Jul 30, 2024 | Q2 Earnings | $88.50 | +2.2% (Medicare expansion) |
| Apr 30, 2024 | Q1 Earnings | $86.20 | +3.1% (acquisition rumors) |
Trend Insight: Positive earnings surprises typically boost AMED by 2-4% within days. The stock shows resilience during healthcare sector volatility, often recovering quickly from minor dips.
📊 6-Month Price Journey (March-August 2025)
Amedisys shares demonstrated remarkable stability with 9% appreciation during this period:
March: $92.63 (regulatory uncertainty)
April: $94.20 (Q1 earnings beat)
May: $96.80 (merger progress optimism)
June: $97.44 (DOJ settlement rumors)
July: $99.31 (earnings strength)
August: $101.01 (merger completion)
Why the steady climb?
🔮 Price Forecast: 2025-2030
2025 (Year-End): $105-110 (post-merger integration benefits) → STRONG BUY
2026: $115-125 (UnitedHealth synergies realization)
2028: $140-160 (aging population tailwinds)
2030: $180-220 (home healthcare market expansion)
Verdict: Exceptional long-term hold potential. Short-term traders should watch for post-earnings entry points.
⚠️ Key Risks vs. Positive Signals
Risks to Consider
- Regulation dependency: 70% Medicare revenue exposure means policy changes directly impact profitability
- Integration challenges: Merging with UnitedHealth’s Optum could create operational disruptions
- Margin pressure: Hospice costs increased 2.9% while revenues grew only 4.1%Hospice News
- CMS proposed cuts: 6.4% Medicare payment reduction for 2026 could hurt margins
Green Lights for 2025
- Merger completion: $3.3 billion deal provides immediate shareholder value
- Revenue diversification: Non-Medicare revenue grew 20% year-over-yearHome Health Care News
- Industry tailwinds: Aging population drives home care demand
- UnitedHealth backing: Access to Optum’s technology and patient network
🛡️ What Should a Beginner Trader Do Today?
- Wait for November dip: Post-earnings typically offers best entry points
- Dollar-cost average: Invest fixed amounts monthly to reduce timing risk
- Set stop-loss at $95: Protect against merger integration surprises
- Allocate wisely: Keep AMED under 15% of healthcare portfolio
Humorous take: “Trading AMED is like home healthcare – sometimes you need patience through recovery periods, but the long-term care pays off!”
✅ How to Buy Amedisys, Inc. (AMED) Shares – Step by Step
| Step | Action | Why It Matters |
|---|---|---|
| 1 | Choose trading platform | Ensure NASDAQ access and low commission rates |
| 2 | Complete account funding | Start with manageable amount ($500+ recommended) |
| 3 | Search “AMED” ticker | Use exact symbol, not company name |
| 4 | Select order type | Limit order at $100-102 range for better entry |
| 5 | Review and execute | Confirm fees under 1% and settlement details |
💡 Why Pocket Option Fits Healthcare Investors
Pocket Option revolutionizes healthcare stock investing with:
- $5 minimum deposit – Test strategies with Amedisys without significant risk
- 60-second verification – Single document upload gets you trading immediately
- 100+ withdrawal methods – Instant access to profits via crypto, e-wallets, or cards
- Real-time healthcare sector data – Monitor AMED alongside industry trends
🌍 Amedisys in 2025: Home Healthcare Transformed
Amedisys dominates the home-based care market with 347 Medicare-certified centers across 38 states, serving 499,000 patients annuallyHome Health Care News. The UnitedHealth acquisition creates America’s largest hospice provider, integrating post-acute care from hospital to home.
Interesting Fact: As part of the DOJ settlement, Amedisys divested 164 facilities across 19 states – representing $528 million in annual revenueHospice News. This strategic pruning actually strengthened their competitive position in core markets!
FAQ
Is Amedisys a good long-term investment after the merger?
Absolutely. UnitedHealth's resources and patient network provide unprecedented growth potential in the expanding home healthcare market.
What percentage of revenue comes from Medicare?
Approximately 70%, but non-Medicare revenue grew 20% year-over-year, showing successful diversification.
How does the DOJ settlement affect shareholders?
Positively - the $1.1 million penalty was minor compared to the $3.3 billion acquisition value, and divestitures actually optimized their market focus.
Should I buy before or after November earnings?
Historically, post-earnings offers better entry points, but long-term investors can start position-building now.
What's the biggest risk for AMED stock?
Medicare reimbursement cuts - the proposed 6.4% reduction for 2026 could impact profitability if implemented fully.
Signals
Sign up for more like this
Customize your newsfeed with content you're actually interested in — get up-to-date personalized newsletter in your inbox.
Your comment
Comments are pre-moderated to ensure they comply with our blog guidelines.